Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leningrado 5 in Hypertension
NCT03814148Phase 3Withdrawn
- Sponsor
- EMS
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of indapamide + levamlodipine in hypertension (HTN) (2 arms), sponsored by EMS. Primary endpoint: Change in systolic blood pressure levels at 70 days. Planned start Jun 2019; status: withdrawn.
02
Drugs
indapamide + levamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03814148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814148.